13F Holdings
中文EN

PLRX PLIANT THERAPEUTICS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1746473 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY48.5%
TTM EPS YoY49.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-55.3%
ROA-40.5%
ROIC (approx.)-63.7%
Asset turnover—

Leverage & solvency

Liabilities / assets25.5%
Debt / equity0.00x
Current ratio8.05x
Interest coverage-698.18x

Cash quality & payout

Operating cash flow / net income0.74x
Accruals ratio-10.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$0$0$1.58M$9.69M$7.57M
R&D expense$109.16M$169.31M$127.80M$96.94M$77.55M
SG&A expense$47.22M$59.05M$57.93M$39.95M$27.56M
Operating income-$156.37M-$228.37M-$184.15M-$127.20M-$97.53M
Interest expense$2.56M$3.02M$1.27M$791,000$0
Pretax income-$149.30M-$210.30M-$161.30M-$123.30M-$97.30M
Income tax$0$0$0$0$0
Net income-$149.34M-$210.30M-$161.34M-$123.32M-$97.26M
EBITDA-$154.68M-$226.24M-$182.30M-$125.38M-$96.00M
EPS (basic)-2.43-3.47-2.75-2.94-2.71
EPS (diluted)-2.43-3.47-2.75-2.94-2.71
Dividends declared per share0.000.000.000.000.00
Weighted avg. shares (diluted)61.37M60.54M58.72M42.02M35.85M
Balance sheet
Cash & equivalents$45.45M$72.67M$64.72M$33.68M$51.66M
Short-term investments$145.50M$284.54M$431.01M$297.50M$148.93M
Receivables——$0$1.98M$2.00M
Current assets$196.45M$362.26M$505.50M$340.31M$209.44M
PP&E, net$2.94M$5.53M$3.57M$4.49M$4.61M
Total assets$225.23M$396.95M$512.15M$350.61M$221.22M
Current liabilities$16.36M$33.22M$28.52M$23.91M$16.83M
Long-term debt$0$30.21M$10.05M$9.93M$0
Total debt$0$30.21M$10.05M$9.93M$0
Total liabilities$44.02M$92.87M$38.58M$37.27M$22.16M
Shareholders' equity$181.21M$304.08M$473.58M$313.34M$199.06M
Net debt-$45.45M-$42.46M-$54.66M-$23.75M-$51.66M
Shares outstanding61.45M60.86M59.92M48.94M36.08M
Cash flow statement
Operating cash flow-$128.34M-$155.50M-$116.36M-$94.63M-$75.44M
Capital expenditure$374,000$3.85M$921,000$1.76M$1.95M
Free cash flow-$128.71M-$159.35M-$117.28M-$96.39M-$77.40M
Investing cash flow$134.29M$140.34M-$127.01M-$150.20M$73.70M
Financing cash flow-$31.70M$23.12M$274.40M$226.85M$2.53M
Depreciation & amortization$1.70M$2.12M$1.84M$1.82M$1.53M
Stock-based compensation$26.23M$37.63M$44.48M$22.60M$10.44M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.